RICARDO GALHARDONI
Projetos de Pesquisa
Unidades Organizacionais
2 resultados
Resultados de Busca
Agora exibindo 1 - 2 de 2
- Effects of cerebellar neuromodulation in movement disorders: A systematic review(2018) FRANCA, Carina; ANDRADE, Daniel Ciampi de; TEIXEIRA, Manoel Jacobsen; GALHARDONI, Ricardo; SILVA, Valquiria; BARBOSA, Egberto Reis; CURY, Rubens GisbertBackground: The cerebellum is involved in the pathophysiology of many movement disorders and its importance in the field of neuromodulation is growing. Objectives: To review the current evidence for cerebellar modulation in movement disorders and its safety profile. Methods: Eligible studies were identified after a systematic literature review of the effects of cerebellar modulation in cerebellar ataxia, Parkinson's disease (PD), essential tremor (ET), dystonia and progressive supranuclear palsy (PSP). Neuromodulation techniques included transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS) and deep brain stimulation (DBS). The changes in motor scores and the incidence of adverse events after the stimulation were reviewed. Results: Thirty-four studies were included in the systematic review, comprising 431 patients. The evaluation after stimulation ranged from immediately after to 12 months after. Neuromodulation techniques improved cerebellar ataxia due to vascular or degenerative etiologies (TMS, tDCS and DBS), dyskinesias in PD patients (TMS), gross upper limb movement in PD patients (tDCS), tremor in ET (TMS and tDCS), cervical dystonia (TMS and tDCS) and dysarthria in PSP patients (TMS). All the neuromodulation techniques were safe, since only three studies reported the existence of side effects (slight headache after TMS, local skin erythema after tDCS and infectious complication after DBS). Eleven studies did not mention if adverse events occurred. Conclusions: Cerebellar modulation can improve specific symptoms in some movement disorders and is a safe and well-tolerated procedure. Further studies are needed to lay the groundwork for new researches in this promising target.
- Latin American and Caribbean consensus on noninvasive central nervous system neuromodulation for chronic pain management (LAC(2)-NIN-CP)(2019) BAPTISTA, Abrahao Fontes; FERNANDES, Ana Mercia B. L.; SA, Katia Nunes; OKANO, Alexandre Hideki; BRUNONI, Andre Russowsky; LARA-SOLARES, Argelia; ISKANDAR, Aziza Jreige; GUERRERO, Carlos; AMESCUA-GARCIA, Cesar; KRAYCHETE, Durval Campos; CAPARELLI-DAQUER, Egas; ATENCIO, Elias; PIEDIMONTE, Fabian; COLIMON, Frantz; HAZIME, Fuad Ahmed; GARCIA, Joao Batista S.; HERNANDEZ-CASTRO, John Jairo; CANTISANI, Jose Alberto Flores; MONTE-SILVA, Katia Karina do; CORREIA, Luis Claudio Lemos; GALLEGOS, Manuel Sempertegui; MARCOLIN, Marco Antonio; RICCO, Maria Antonieta; COOK, Maria Berenguel; BONILLA, Patricia; SCHESTATSKY, Pedro; GALHARDONI, Ricardo; SILVA, Valquiria; BARRERA, William Delgado; CAUMO, Wolnei; BOUHASSIRA, Didier; CHIPCHASE, Lucy S.; LEFAUCHEUR, Jean-Pascal; TEIXEIRA, Manoel Jacobsen; ANDRADE, Daniel Ciampi deIntroduction: Chronic pain (CP) is highly prevalent and generally undertreated health condition. Noninvasive brain stimulation may contribute to decrease pain intensity and influence other aspects related to CP. Objective: To provide consensus-based recommendations for the use of noninvasive brain stimulation in clinical practice. Methods: Systematic review of the literature searching for randomized clinical trials followed by consensus panel. Recommendations also involved a cost-estimation study. Results: The systematic review wielded 24 transcranial direct current stimulation (tDCS) and 22 repetitive transcranial magnetic stimulation (rTMS) studies. The following recommendations were provided: (1) Level A for anodal tDCS over the primary motor cortex (M1) in fibromyalgia, and level B for peripheral neuropathic pain, abdominal pain, and migraine; bifrontal (F3/F4) tDCS and M1 high-definition (HD)-tDCS for fibromyalgia; Oz/Cz tDCS for migraine and for secondary benefits such as improvement in quality of life, decrease in anxiety, and increase in pressure pain threshold; (2) level A recommendation for high-frequency (HF) rTMS over M1 for fibromyalgia and neuropathic pain, and level B for myofascial or musculoskeletal pain, complex regional pain syndrome, and migraine; (3) level A recommendation against the use of anodal M1 tDCS for low back pain; and (4) level B recommendation against the use of HF rTMS over the left dorsolateral prefrontal cortex in the control of pain. Conclusion: Transcranial DCS and rTMS are recommended techniques to be used in the control of CP conditions, with low to moderate analgesic effects, and no severe adverse events. These recommendations are based on a systematic review of the literature and a consensus made by experts in the field. Readers should use it as part of the resources available to decision-making.